Browse our 1,000+ Publications​

Latest Publications

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractoryB-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 resultsfrom a single-arm, multicentre, phase 1/2 study

Kersten M, et al.
Lancet Haematology
September 2026
Authors and Affiliates
Marie José Kersten 1, Maria T Kuipers 2, Pim G N J Mutsaers 3, Evelyne Willems 4, Kirsten Saevels 5, Martin Dreyling 6, Caron Jacobson 7, Michael R Bishop 8, Maarten Zandvliet 9, Stavros Milatos 10, Chiara Lobetti-Bodoni 10, Sandra Blum 10, Kirsten Van Hoorde 11, Jigar Desai 12, Lorenzo Acciarri 13, Margot J Pont 9, Anna van Muyden 9, Omotayo Fasan 12, Joost S P Vermaat 14, Sébastien Anguille 5 1Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands. Electronic address: m.j.kersten@amsterdamumc.nl. 2Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands. 3Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 4Department of Hematology, Centre Hospitalier Universitaire de Liège, Liège, Belgium. 5Division of Hematology and Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium. 6Department of Medicine III, LMU Hospital Munich, Munich, Germany. 7Division of Lymphoma, Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA. 8The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA. 9Galapagos, Leiden, Netherlands; CellPoint, Leiden, Netherlands. 10Galapagos, Basel, Switzerland. 11Open Analytics, Antwerp, Belgium. 12Galapagos, Princeton, NJ, USA. 13Valos, Genoa, Italy. 14Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial

Falchi L, et al.
Lancet Haematology
September 2026
Authors and Affiliates
Lorenzo Falchi 1, Joost S P Vermaat 2, Joshua D Brody 3, Lori Leslie 4, Fritz Offner 5, Jacob Haaber Christensen 6, Marcel Nijland 7, David Belada 8, Björn Engelbrekt Wahlin 9, Kristina Drott 10, Pilar Gomez Prieto 11, Kateřina Kopečkova 12, Alejandro Martín García-Sancho 13, Jian P Mei 14, Işıl Altıntaş 15, Malene Risum 16, Aidan Reilly 17, Jun Zou 17, Pau Abrisqueta 18 1Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: falchil@mskcc.org. 2Leiden University Medical Center, Leiden, Netherlands. 3Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4Lymphoma Division, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack, NJ, USA. 5Universitair Ziekenhuis Gent, Ghent, Belgium. 6Odense University Hospital, Odense, Denmark. 7University Medical Center Groningen and University of Groningen, Groningen, Netherlands. 8Hospital and Faculty of Medicine, Charles University, Hradec Králové, Czech Republic. 9Karolinska Institutet, Stockholm, Sweden. 10Skåne University Hospital, Lund, Sweden. 11Hospital Universitario La Paz, Madrid, Spain. 12Motol University Hospital, Charles University, Prague, Czech Republic. 13Hospital Universitario de Salamanca, IBSAL, CIBERONC, University of Salamanca, Salamanca, Spain. 14AbbVie, North Chicago, IL, USA. 15Genmab, Utrecht, Netherlands. 16Genmab, Copenhagen, Denmark. 17Genmab, Plainsboro, NJ, USA. 18Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes

Gould P, et al.
Haematologica
August 2026
Authors and Affiliates
*Patrick Gould,1,2 *Devyn Coskey,1 Xin Ma,1 Shikun Wang,1 Sonia Godbole,3 David Bond,3 Andrew Ip,4 Snegha Ananth,5 Shaunak Varma,6 Emily Ayers,6 Rachel Faden,7 Cassandra Gillespie,7 Basem William,7 Ryan Jacobs,8 Bei Hu,8 Jake Lattin,9 David Russler-Germain,9 Michele Stanchina,10 Ashley Rose,10 Michael Randall,11 Michael Spinner,11 Vidiya Srikakulapu,12 Praveen Ramakrishnan Geethakumari,12 Alan Skarbnik,13 David W. Chitty,14 Mazie Tsang,15 Cassandra Duarte,16 Ajay Major,16 Allison M. Bock,17 Kelsey Baron,17 Brian Hess,18 Seda Tolu,1 Barbara Pro,1 Supriya Vaidya,1 Jennifer E. Amengual,1 Ran Reshef,1 Hua-Jay J. Cherng1# 1Columbia University Irving Medical Center, New York, NY; 2Memorial Sloan Kettering Cancer Center, New York, NY; 3Ohio State University, Columbus, OH; 4Hackensack University Medical Center, Hackensack, NJ; 5University of Nebraska, Omaha, NE; 6University of Virginia, Charlottesville, VA; 7OhioHealth, Columbus, OH; 8Levine Cancer Institute, Atrium Health Wake Forest, Charlotte, NC; 9Washington University in St. Louis, St. Louis, MO; 10University of Miami, Miami, FL; 11University of California San Francisco, San Francisco, CA; 12University of Texas, Southwestern, Dallas, TX; 13Novant Health Cancer Institute, Charlotte, NC; 14Northwell Health, Lake Success, NY; 15Mayo Clinic Arizona, Phoenix, AZ; 16University of Colorado, Aurora, CO; 17University of Utah, Salt Lake City, UT; 18Medical University of South Carolina, Charleston, SC *P. G. and D. C contributed equally to this study

Tracking B-cell Depletion and Reconstitution using Next-Generation Immunosequencing

Lee L, et al.
Blood Immunology & Cellular Therapy
August 2026
Authors and Affiliates
Lik Wee Lee (Adaptive Biotechnologies Corp., United States) Rohaum Hamidi (Stanford University School of Medicine, United States) Christina Baggott (Stanford University, United States) Liora Schultz (Columbia University Medical Center, United States) Ilan Kirsch (Adaptive Biotechnologies, United States)

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004

Wierda W, et al.
Blood
July 2026
Authors and Affiliates
William Wierda (The University of Texas MD Anderson Cancer Center, United States) Kathleen Dorritie (UPMC, United States) Jordan Gauthier (Fred Hutchinson Cancer Research Center, United States) Rajneesh Nath (Banner MD Anderson Cancer Center, United States) Thomas Kipps (University of California, San Diego School of Medicine, United States) Peter Riedell (The David and Etta Jonas Center for Cellular Therapy, University of Chicago, United States) Herbert Eradat (UCLA, United States) Saad Kenderian (Mayo Clinic, United States) Mohamed Kharfan-Dabaja (Mayo Clinic, United States) Nirav Shah (Medical College of Wisconsin, United States) Scott Solomon (Northside Hospital Cancer Institute, United States) Deborah Stephens (Lineberger Cancer Center, University of North Carolina, United States) Daniel Ermann (Huntsman Cancer Institute, University of Utah, United States) Jon Arnason (Beth Israel Deaconess Medical Center, United States) Abhinav Deol (Wayne State University, United States) Tatyana Feldman (Hackensack University Medical Center, United States) Charalambos Andreadis (University of California San Francisco, United States) Monalisa Ghosh (University of Michigan, United States) Shuo Ma (Northwestern University, United States) Stephen Schuster (Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, United States) Usama Gergis (Thomas Jefferson University, United States) Julie Vose (University of Nebraska Medical Center, United States) Jacob Soumerai (Mass General Brigham Cancer Institute, United States) Koen van Besien (Seidman Cancer Center, United States) Sherilyn Tuazon (Bristol Myers Squibb, United States) Serena Perna (Bristol Myers Squibb, United States) San-San Ou (Bristol Myers Squibb, United States) Revathi Ananthakrishnan (Bristol Myers Squibb, United States) Neha Rane (Bristol Myers Squibb, United States) Eniko Papp (Bristol Myers Squibb, United States) Sahar Ansari (Bristol Myers Squibb, United States) Ethan Thompson (Bristol Myers Squibb, United States) Abood Okal (Bristol Myers Squibb, United States) Leanne Peiser (Bristol Myers Squibb, United States) Yizhe Chen (Bristol Myers Squibb, United States) Sanhita Sengupta (Bristol Myers Squibb, United States) Pradipta Ray (Bristol Myers Squibb, United States) Jixian Wang (Bristol Myers Squibb, Switzerland) Tanya Siddiqi (City of Hope Orange County, United States)

Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage

Azavedo R, et al.
Leukemia
July 2026
Authors and Affiliates
Roberta S. Azevedo 1,3, Elias Jabbour 1,3, Nitin Jain1, Fadi G. Haddad 1, Partow Kebriaei 2, Issa Khouri 2, Elizabeth J. Shpall2, Richard Champlin 2, Omer Karrar 1, Manuel Maroun 1, Jayastu Senapati 1, Eitan Kugler1, Rebecca S. Garris1, Farhad Ravandi 1, Hagop Kantarjian 1 and Nicholas J. Short 1 1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, USA. 2The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, USA. 3These authors contributed equally: Roberta S. Azevedo, Elias Jabbour.

MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL

Altintas I, et al.
Blood Advances
July 2026
Authors and Affiliates
Isil Altintas (Genmab, Netherlands) Christopher Morehouse (Genmab, United States) Elena Favaro (Genmab A/S, Denmark) Ali Rana (Genmab, United States) John Karavitis (Genmab, United States) Edith Szafer Glusman (AbbVie, United States) Kevin Zhao (AbbVie, United States) Kim Linton (The University of Manchester, United Kingdom) Alexey Danilov (City of Hope, United States) Ann LaCasce (Dana-Farber Cancer Institute, United States) Lorenzo Falchi (Memorial Sloan Kettering Cancer Center, United States) Jessica Okosun (Barts Cancer Institute, Queen Mary University of London, United Kingdom) Tahamtan Ahmadi (Genmab, United States) Mark Fereshteh (Genmab, United States) Maria Jure-Kunkel (Genmab, United States) David Soong (Genmab, United States) Andrew Steele (Genmab, United States)

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs

Soumerai J, et al.
June 2026
Authors and Affiliates
Jacob D. Soumerai1, Meghan C. Thompson2, Ahmet Dogan2, Venkatraman Seshan2, Kelsey L. Flaherty2, Natalie Slupe2, Jason Carter2, Ephraim Hochberg1, Jeffrey A. Barnes1, Jeremy S. Abramson1, Ariela Noy2, Cole􀆩e Owens2, Maria Lia Palomba2, Anita Kumar2, Lindsey Roeker3, Ronald W. Takvorian1, Zachary D. Epstein-Peterson2, Mark B. Geyer2, Gilles Salles2, Robert Stuver2, Philip Caron2, Prioty Islam2, Tamanna Haque2, Paola Ghione2, Raphael E. Steiner2, Pallawi Torka2, Kevin A. David2, Jennifer K. Lue2, Paul A. Hamlin2, Alison Moskowitz2, Lorenzo Falchi2, J. Erika Haydu1, P. Connor Johnson1, Joanna Mi2, Neena Mahajan2, Jessica Pendleton2, Alyssa Labarre2, Maria Chabowska2, Morgan Choma2, Clare Grieve2, Ashlee Joseph2, Colleen Dorsey2, Jamila Brutus2, Rosalba Mar􀆟gne􀆫1, Rachel Nazzaro1, Jayne Coyle1, Olivia Maas1, De Voysa Meemanage1, Akshata Kakolu1, Cameron Gordon1, Eshani Baez1, Bernade􀆩e Bea􀆩y1, Athina Apazidis1, Michelle Gulloto1, Sherry Ratcliff1, Jamie Hirata3, Mina Shahkarami4, Allison P. Jacob5, Omar Abdel-Wahab2, Andrew D. Zelenetz2 1- Mass General Brigham Cancer Insitute, Boston, MA 2- Memorial Sloan Ke􀆩ering Cancer Center, New York, NY 3- BeOne Medicines, Ltd., San Mateo, CA 4- Genentech Inc., South San Francisco, CA 5- Adap􀆟ve Biotechnologies, Sea􀆩le, WA

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

Marc Raab, et al.
Nature Medicine
June 2026
Authors and Affiliates
Marc S. Raab 1,22 , Niels Weinhold 1,22, K. Martin Kortüm 2, Jan Krönke 3,4, Roland Fenk5, Katja Weisel 6, Lilli Podola1, Uta Bertsch1, Alexander Brobeil7, Julia Mersi2, Stefanie Huhn1, Ryan Arlinghaus8, Michael Hundemer1, Stephan R. Bohl3, Elias K. Mai 1, Natalie Schub9, Johannes Waldschmidt 2, Florian Bassermann 10,11,12, Carsten Müller-Tidow 1, Christoph Heuck13, Caline Sakabedoyan14, Josephine Khan15, Elena Ershova16, Bas D. Koster 17, Monika Engelhardt18, Mathias Hänel19, Hans Salwender 20, Raphael Teipel21, Hartmut Goldschmidt 1, Hermann Einsele 2 & Leo Rasche 2 on behalf of the GMMG-HD10/DSMM-XX (MajesTEC-5) investigators 1Heidelberg Myeloma Center and GMMG Study Group, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany. 2Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany. 3Department of Hematology, Oncology, and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. 4Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Berlin, Berlin, Germany. 5Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. 6University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 7Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. 8Coordination Centre for Clinical Trials (KKS), University Hospital Heidelberg, Heidelberg, Germany. 9Department of Internal Medicine II, Division of Stem Cell Transplantation and Immunotherapy, Universitätsklinikum Schleswig-Holstein (UKSH) Campus Kiel, Kiel, Germany. 10Department of Medicine III, TUM Klinikum, Technische Universität München, München, Germany. 11Deutsches Konsortium für Translationale Krebsforschung (DKTK), Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany. 12Bayerisches Zentrum für Krebsforschung (BZKF), Munich, Germany. 13Johnson & Johnson, Spring House, PA, USA. 14Johnson & Johnson, Paris, France. 15Johnson & Johnson, High Wycombe, UK. 16Johnson & Johnson, Beerse, Belgium. 17Johnson & Johnson, Leiden, The Netherlands. 18Department of Hematology, Oncology and Stem Cell Transplantation, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 19Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany. 20Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona and Asklepios Klinik St. Georg, Hamburg, Germany. 21Medizinische Klinik und Poliklinik I Universitätsklinikum Carl Gustav Carus an der Technische Universität Dresden, Dresden, Germany.

Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation

Ginosyan A, et al.
Clinical Lymphoma Myeloma & Leukemia
June 2026
Authors and Affiliates
Anush A Ginosyan 1, Karam Ashouri 1, Tiffany Chen 2, Sophie Grove 1, Elaine Huang 1, Brian Hom 1, Vinay Nittur 1, Blake Adnani 1, Jennifer Hwang 1, Mollee Chu 1, Robert Ireland 1, Brandon Ann 1, Lauren Ford 1, Lucas Humayun 1, Arsine Kolanjian 1, Mihir Baya 1, Danielle Hong 1, Preet Chaudhary 2, Imran Siddiqi 3, Amir Ali 4, Karrune Woan 2, Eric Leon Tam 2, George Yaghmour 5 1Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA. 2Jane Anne Nohl Division of Hematology and Center for the Study of Blood Disease, Division of Hematology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. 3Department of Pathology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. 4Department of Pharmacy, University of Southern California (USC), Norris Comprehensive Cancer Center, Los Angeles, CA. 5Jane Anne Nohl Division of Hematology and Center for the Study of Blood Disease, Division of Hematology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address: george.yaghmour@med.usc.edu.
Previous Next